GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (HKSE:02186) » Definitions » Degree of Financial Leverage

Luye Pharma Group (HKSE:02186) Degree of Financial Leverage : -1.09 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Luye Pharma Group's Degree of Financial Leverage for the quarter that ended in Dec. 2023 was -1.09. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Luye Pharma Group's Degree of Financial Leverage or its related term are showing as below:

HKSE:02186's Degree of Financial Leverage is ranked better than
93.2% of 1044 companies
in the Drug Manufacturers industry
Industry Median: 0.96 vs HKSE:02186: -1.09

Luye Pharma Group Degree of Financial Leverage Historical Data

The historical data trend for Luye Pharma Group's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Degree of Financial Leverage Chart

Luye Pharma Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 1.86 1.57 -2.29 -1.09

Luye Pharma Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 1.76 -2.29 -0.70 -1.09

Competitive Comparison of Luye Pharma Group's Degree of Financial Leverage

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luye Pharma Group's Degree of Financial Leverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's Degree of Financial Leverage falls into.



Luye Pharma Group Degree of Financial Leverage Calculation

Luye Pharma Group's Degree of Financial Leverage for the quarter that ended in Dec. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( 0.156 (Dec. 2023) / 0.194 (Dec. 2022) - 1 )/( 1504.552 (Dec. 2023) / 1274.749 (Dec. 2022) - 1 )
=-0.1959/0.1803
=-1.09***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Luye Pharma Group  (HKSE:02186) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Luye Pharma Group Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Luye Pharma Group (HKSE:02186) Business Description

Traded in Other Exchanges
Address
No. 15 Chuang Ye Road, High-tech Industrial Development Zone, Shandong, Yantai, CHN, 264003
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
Liu Dianbo 2301 Trustee
Luye Life Sciences Group Ltd 2201 Interest of corporation controlled by you
Luye Pharma Holdings Ltd. 2201 Interest of corporation controlled by you
Nelumbo Investments Limited 2201 Interest of corporation controlled by you
Shorea Lbg 2201 Interest of corporation controlled by you
Luye Pharmaceutical Investment Co., Ltd. 2101 Beneficial owner
Ginkgo (ptc) Limited 2301 Trustee
Luye Pharmaceutical International Co., Ltd. 2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Hillhouse Nev Holdings Limited 2101 Beneficial owner
Hillhouse Investment Management, Ltd. 2102 Investment manager
Hillhouse Fund V, L.p. 2201 Interest of corporation controlled by you
Xin Ye Sheng Wu Yi Yao Kong Gu You Xian Gong Si
Yang Yu Fen

Luye Pharma Group (HKSE:02186) Headlines

No Headlines